Tyrosine Hydroxylase Inhibitors and Dopamine Receptor Agonists Combination Therapy for Parkinson’s Disease
International Journal of Molecular Sciences · 24.04.2024 · 25 (9) · 4643
DOI: 10.3390/ijms25094643 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 24.04.2024. Verfasst von Ling Xiao Yi und 2 weiteren Autor:innen. Beteiligte Einrichtung: National Neuroscience Institute of Singapore, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore. Hauptthemen laut MEDLINE: Dopamine Agonists, Parkinson Disease, Tyrosine 3-Monooxygenase. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Medical Research Council, Duke-NUS Medical School, Singapore National Medical Research Council.
Abstract (Originalsprache)
There are currently no disease-modifying therapies for Parkinson’s disease (PD), a progressive neurodegenerative disorder associated with dopaminergic neuronal loss. There is increasing evidence that endogenous dopamine (DA) can be a pathological factor in neurodegeneration in PD. Tyrosine hydroxylase (TH) is the key rate-limiting enzyme for DA generation. Drugs that inhibit TH, such as alpha-methyltyrosine (α-MT), have recently been shown to protect against neurodegeneration in various PD models. DA receptor agonists can activate post-synaptic DA receptors to alleviate DA-deficiency-induced PD symptoms. However, DA receptor agonists have no therapeutic effects against neurodegeneration. Thus, a combination therapy with DA receptor agonists plus TH inhibitors may be an attractive therapeutic approach. TH inhibitors can protect and promote the survival of remaining dopaminergic neurons in PD patients’ brains, whereas DA receptor agonists activate post-synaptic DA receptors to alleviate PD symptoms. Additionally, other PD drugs, such as N-acetylcysteine (NAC) and anticholinergic drugs, may be used as adjunctive medications to improve therapeutic effects. This multi-drug cocktail may represent a novel strategy to protect against progressive dopaminergic neurodegeneration and alleviate PD disease progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Neuroscience Institute of Singapore, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
- Department of Neurology, Singapore General Hospital, Outram Road, Singapore 169608, Singapore.
- Signature Research Program in Neuroscience and Behavioral Disorders, Duke-NUS Graduate Medical School Singapore, 8 College Road, Singapore 169857, Singapore.
ORCID-Profile: Ling Xiao Yi, Zhi Dong Zhou
Förderung
- National Medical Research Council
- Duke-NUS Medical School
- Singapore National Medical Research Council
- clinical translational research program in Parkinson’s disease
- Duke-Duke-NUS
Zitieren
APA
Yi, L. X., Tan, E. K., & Zhou, Z. D. (2024). Tyrosine Hydroxylase Inhibitors and Dopamine Receptor Agonists Combination Therapy for Parkinson’s Disease. International Journal of Molecular Sciences, 25(9), 4643. https://doi.org/10.3390/ijms25094643
Vancouver
Yi LX, Tan EK, Zhou ZD. Tyrosine Hydroxylase Inhibitors and Dopamine Receptor Agonists Combination Therapy for Parkinson’s Disease. International Journal of Molecular Sciences. 2024;25(9):4643. doi:10.3390/ijms25094643
BibTeX
@article{Yi2024,
author = {Yi, Ling Xiao and Tan, Eng King and Zhou, Zhi Dong},
title = {Tyrosine Hydroxylase Inhibitors and Dopamine Receptor Agonists Combination Therapy for Parkinson’s Disease},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {9},
pages = {4643},
doi = {10.3390/ijms25094643}
}
EUVIMED